HitGen Inc.
 | This article reads like a press release or a news article or is largely based on routine coverage or sensationalism. (June 2021) |
Native name | 成都先导药物开发股份有限公司 |
|---|---|
| Public company | |
| Traded as | SSE: 688222.SH |
| ISIN | 🆔 |
| Industry | Biotechnology and Pharmaceuticals |
| Founded 📆 | 2012 |
| Founder 👔 | Jin Li (Chairman and CEO) |
| Headquarters 🏙️ | Chengdu, China |
Number of locations | 3 (2021) |
Area served 🗺️ | Worldwide |
Key people | Jin Li (Chairman and CEO), Barry Morgan (CSO) |
| Services | DEL, FBDD, SBDD |
| Members | |
Number of employees | ~500 |
| Subsidiaries | Vernalis Research, HitGen Pharmaceuticals Inc. |
| 🌐 Website | hitgen.com/en |
| 📇 Address | |
| 📞 telephone | |
HitGen Inc. (成都先导药物开发股份有限公司) is a biotechnology company headquartered in Chengdu, China. HitGen has established a drug discovery research platform for small molecules and nucleic acid drugs centred on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies.
History
HitGen was founded in 2012, initially focusing on the development and application of DEL technology to significantly increase the molecular diversity for the screening of new chemical leads or hits to interact with new drug targets. Since then, HitGen has formed partnerships with a majority of the world's top 20 pharmaceutical companies, including Merck and Janssen, as well as over 100 biotechs and research foundations to help advance their drug discovery projects on an exclusive basis.[1][2][3][4][5][6] In addition to these external collaborations, HitGen has a number of assets within their own internal drug development pipeline, several of which have reached early stage clinical trials. These include, HG146, a Class I/IIb-selective HDAC inhibitor for multiple myeloma and selected solid tumour indications, and HG030, a second-generation TRK inhibitor, also for solid tumour indications. Both are currently in Phase 1 clinical trials, alongside HG381, an IV injectable STING agonist that leverages innate immunity to fight cancer.[7][8][9][10]
In 2018, CDH Investments led a 250M RMB ($39M) Series B round in HitGen.[11] In April 2020, HitGen was the first company from Southwest China to list on the Shanghai Stock Exchange STAR Market.[6][12]
HitGen has a US subsidiary, HitGen Pharmaceuticals Inc., based in Houston, Texas and in December 2020 acquired Vernalis Research, a biotechnology company specialising in fragment-based and structure-based drug discovery,[13][14][15] based in Cambridge, UK.[16]
People
HitGen was founded by Jin Li, who currently serves as HitGen's Chairman and Chief Executive Officer. Li previously held global leadership positions at AstraZeneca.[7][11][17] The Chief Scientific Officer is Barry Morgan, who was previously a VP at GSK and SVP at Praecis Pharmaceuticals, where he was a primary inventor of DNA Encoded Library Technology.[18]
References
- ↑ "Merck, HitGen expand DNA library screening collaboration". FierceBiotech. 6 August 2018. Retrieved 2021-05-11.
- ↑ "HitGen Announces Strategic Collaboration with Janssen to Design and Build Novel DNA-Encoded Libraries". www.businesswire.com. 2019-12-09. Retrieved 2021-05-11.
- ↑ "HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Galapagos NV". www.nasdaq.com. Retrieved 2021-05-11.
- ↑ "HitGen and UPPTHERA Enter Into Drug Discovery Research Collaboration". www.businesswire.com. 2021-03-01. Retrieved 2021-05-11.
- ↑ "HitGen and BioAge Announce Research Progress in DNA-Encoded Library Based Drug Discovery Research Collaboration". www.businesswire.com. 2021-04-06. Retrieved 2021-05-11.
- ↑ 6.0 6.1 董志成. "New economy business becomes a growing driver of city development - Chinadaily.com.cn". epaper.chinadaily.com.cn. Retrieved 2021-05-11.
- ↑ 7.0 7.1 "Jin LI – Chairman & CEO, HitGen, China". PharmaBoardroom. Retrieved 2021-05-11.
- ↑ "HitGen's HG381 approved as China's first clinical STING agonist". www.medicilon.com. Retrieved 2021-05-11.
- ↑ HitGen Inc. (2019-10-15). "A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma".
- ↑ "HitGen Licenses Its Trk/ROS1 Inhibitor HG030 to Baiyunshan for Development and Commercialisation in China". BioSpace. Retrieved 2021-05-11.
- ↑ 11.0 11.1 "CDH Investments Leads $39M Series B In Drug Discovery Firm HitGen-CDH". www.cdhfund.com. Retrieved 2021-05-11.
- ↑ "Chinese biotech firm uses DNA to discover new drugs". news.cgtn.com. Retrieved 2022-01-11.
- ↑ Davis, Ben J.; Roughley, Stephen D. (2017), "Fragment-Based Lead Discovery", Annual Reports in Medicinal Chemistry, Elsevier, 50, pp. 371–439, doi:10.1016/bs.armc.2017.07.002, ISBN 978-0-12-813069-8, retrieved 2021-05-11
- ↑ Erlanson, Daniel A.; Fesik, Stephen W.; Hubbard, Roderick E.; Jahnke, Wolfgang; Jhoti, Harren (September 2016). "Twenty years on: the impact of fragments on drug discovery". Nature Reviews Drug Discovery. 15 (9): 605–619. doi:10.1038/nrd.2016.109. ISSN 1474-1776. PMID 27417849. Unknown parameter
|s2cid=ignored (help) - ↑ Hubbard, Roderick E.; Murray, James B. (2011), "Experiences in Fragment-Based Lead Discovery", Methods in Enzymology, Elsevier, 493: 509–531, doi:10.1016/b978-0-12-381274-2.00020-0, ISBN 978-0-12-381274-2, PMID 21371604, retrieved 2021-05-11
- ↑ "HitGen to Acquire Vernalis, a Leader in Structure-Based Drug Discovery". www.businesswire.com. 2020-10-12. Retrieved 2021-05-11.
- ↑ Watanabe, Anna Nishino,Akira Shimizu,Shohei Yasuda,Kentaro. "Pharmacy of the world: China's quest to be the No. 1 drugmaker". Nikkei Asia. Retrieved 2022-05-19.
- ↑ "The history and use of DNA-Encoded Libraries in drug discovery". talks.ox.ac.uk. Retrieved 2021-05-11.
This article "HitGen Inc." is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:HitGen Inc.. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
